76
Participants
Start Date
January 14, 2025
Primary Completion Date
February 9, 2028
Study Completion Date
February 11, 2030
Tagraxofusp
Tagraxofusp will be administered by intravenous infusion for 3 consecutive days during each 28-day cycle.
Venetoclax
Venetoclax will be administered as an oral tablet (400 milligrams \[mg\]) daily, with ramp up in Cycle 1, and should be continued at target dose (400 mg) for the remainder of Cycle 1 and subsequent cycles of 28 days each.
Azacitidine
Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
RECRUITING
Concord Repatriation General Hospital, Concord
RECRUITING
St. Vincents Hospital, Fitzroy
RECRUITING
Austin Hospital, Heidelberg
RECRUITING
Box Hill Hospital, Box Hill
RECRUITING
Monash Medical Centre, Clayton
NOT_YET_RECRUITING
Townsville Hospital, Townsville
RECRUITING
Royal Adelaide Hospital, Adelaide
NOT_YET_RECRUITING
Royal Perth Hospital, Perth
RECRUITING
NYU Langone Health, New York
RECRUITING
Columbia University Irving Medical Center, New York
NOT_YET_RECRUITING
North Shore University Hospital, Manhasset
NOT_YET_RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
NOT_YET_RECRUITING
Sydney Kimmel (Thomas Jefferson University), Philadelphia
RECRUITING
Novant Health Derrick L Davis Cancer Center, Winston-Salem
RECRUITING
Novant Health Presbyterian Medical Center, Charlotte
RECRUITING
AdventHealth Cancer Institute, Orlando
RECRUITING
University of Miami, Miami
RECRUITING
Sarah Cannon, the Cancer Institute of HCA Healthcare, Nashville
RECRUITING
Tennessee Oncology, Nashville
NOT_YET_RECRUITING
Cleveland Clinic Foundation, Cleveland
NOT_YET_RECRUITING
Henry Ford Health, Detroit
NOT_YET_RECRUITING
University of Chicago, Chicago
RECRUITING
Washington University - Siteman Cancer Center, St Louis
RECRUITING
Baylor Scott & White Health, Dallas
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
Huntsman Cancer Institute, Salt Lake City
RECRUITING
University of California, Los Angeles, Los Angeles
NOT_YET_RECRUITING
Stanford University Medical Center, Palo Alto
RECRUITING
Dana Farber Cancer Institute (DFCI), Boston
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
John Theurer Cancer Center - Hackensack Meridian Health, Hackensack
RECRUITING
Rutgers Cancer Institute, New Brunswick
Stemline Therapeutics, Inc.
INDUSTRY